163 related articles for article (PubMed ID: 34849918)
1. Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease: Results from a Phase 1 Randomized Trial.
Zhang W; Scalori A; Fuh F; McBride J; She G; Kierkus J; Korczowksi B; Li R; Abouhossein M; Kadva A; Park KT; Tang MT
Inflamm Bowel Dis; 2022 Sep; 28(9):1348-1356. PubMed ID: 34849918
[TBL] [Abstract][Full Text] [Related]
2. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
[TBL] [Abstract][Full Text] [Related]
3. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
[TBL] [Abstract][Full Text] [Related]
4. Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program.
Sandborn WJ; Vermeire S; Tyrrell H; Hassanali A; Lacey S; Tole S; Tatro AR;
Adv Ther; 2020 Jul; 37(7):3417-3431. PubMed ID: 32445184
[TBL] [Abstract][Full Text] [Related]
5. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038
[TBL] [Abstract][Full Text] [Related]
6. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis.
Rutgeerts PJ; Fedorak RN; Hommes DW; Sturm A; Baumgart DC; Bressler B; Schreiber S; Mansfield JC; Williams M; Tang M; Visich J; Wei X; Keir M; Luca D; Danilenko D; Egen J; O'Byrne S
Gut; 2013 Aug; 62(8):1122-30. PubMed ID: 22717454
[TBL] [Abstract][Full Text] [Related]
7. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
[TBL] [Abstract][Full Text] [Related]
8. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
Rubin DT; Dotan I; DuVall A; Bouhnik Y; Radford-Smith G; Higgins PDR; Mishkin DS; Arrisi P; Scalori A; Oh YS; Tole S; Chai A; Chamberlain-James K; Lacey S; McBride J; Panés J;
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):17-27. PubMed ID: 34798036
[TBL] [Abstract][Full Text] [Related]
9. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.
Tang MT; Keir ME; Erickson R; Stefanich EG; Fuh FK; Ramirez-Montagut T; McBride JM; Danilenko DM
Aliment Pharmacol Ther; 2018 Jun; 47(11):1440-1452. PubMed ID: 29601644
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis.
Wei X; Gibiansky L; Wang Y; Fuh F; Erickson R; O'Byrne S; Tang MT
J Clin Pharmacol; 2018 Mar; 58(3):386-398. PubMed ID: 29178491
[TBL] [Abstract][Full Text] [Related]
11. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis.
Vermeire S; Lukáš M; Magro F; Adsul S; Lindner D; Rosario M; Roth J; Danese S
J Crohns Colitis; 2020 Sep; 14(8):1066-1073. PubMed ID: 32060515
[TBL] [Abstract][Full Text] [Related]
12. Etrolizumab for induction of remission in ulcerative colitis.
Rosenfeld G; Parker CE; MacDonald JK; Bressler B
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011661. PubMed ID: 26630451
[TBL] [Abstract][Full Text] [Related]
13. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study.
Atia O; Shavit-Brunschwig Z; Mould DR; Stein R; Matar M; Aloi M; Ledder O; Focht G; Urlep D; Hyams J; Broide E; Weiss B; Levine J; Russell RK; Turner D
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):31-42. PubMed ID: 36306803
[TBL] [Abstract][Full Text] [Related]
14. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.
Vermeire S; O'Byrne S; Keir M; Williams M; Lu TT; Mansfield JC; Lamb CA; Feagan BG; Panes J; Salas A; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Tew GW; Luca D; Tang MT; Diehl L; Eastham-Anderson J; De Hertogh G; Perrier C; Egen JG; Kirby JA; van Assche G; Rutgeerts P
Lancet; 2014 Jul; 384(9940):309-18. PubMed ID: 24814090
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn's Disease: Results from the Phase 2 HUBBLE Study.
Hyams JS; Turner D; Cohen SA; Szakos E; Kowalska-Duplaga K; Ruemmele F; Croft NM; Korczowski B; Lawrence P; Bhatia S; Kadali H; Chen C; Sun W; Rosario M; Kabilan S; Treem W; Rossiter G; Lirio RA
J Crohns Colitis; 2022 Aug; 16(8):1243-1254. PubMed ID: 35301512
[TBL] [Abstract][Full Text] [Related]
16. Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers.
Zhang W; Tyrrell H; Ding HT; Pulley J; Boruvka A; Erickson R; Abouhossein M; Ravanello R; Tang MT
Adv Ther; 2021 May; 38(5):2418-2434. PubMed ID: 33778929
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
[TBL] [Abstract][Full Text] [Related]
18. An Open-Label Tolerability and Actual-Use Human Factors Study of Etrolizumab Autoinjector in Healthy Volunteers.
Tyrrell H; Ravanello R; Pulley J; Tang MT; Zhang W; Abouhossein M; Tole S
Adv Ther; 2021 May; 38(5):2406-2417. PubMed ID: 33778928
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
20. Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.
Tew GW; Hackney JA; Gibbons D; Lamb CA; Luca D; Egen JG; Diehl L; Eastham Anderson J; Vermeire S; Mansfield JC; Feagan BG; Panes J; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Kirby JA; Irving PM; De Hertogh G; Van Assche GA; Rutgeerts P; O'Byrne S; Hayday A; Keir ME
Gastroenterology; 2016 Feb; 150(2):477-87.e9. PubMed ID: 26522261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
